

Regulation of T-cell-mediated pathology: The revival of suppressor cells

REBECCA S. MCHUGH

Malaghan Institute of Medical Research, Wellington, New Zealand

Diseases resulting from an overactive (autoimmunity) or underactive (chronic parasitic infections) immune response have long been subjects of investigation. The phenomenon of active immunosuppression was observed decades ago, but not until the recent advances in cellular immunology was credibility established. Within the past 10 years, a subset of CD4⁺ T cells expressing the alpha chain of the interleukin (IL)-2 receptor (CD25) has been identified in mice and humans as potent suppressors of T-cell responses. In addition to naturally occurring CD4⁺ CD25⁺ T cells, many T cells can be induced to acquire regulatory functions.

Although first identified as suppressors of autoimmunity, CD4⁺ CD25⁺ T cells have been shown to control immune responses to autoantigens, alloantigens, tumor antigens, and foreign pathogenic antigens. It is now theorized that their presence is not to control self-reactive T cells, but rather to maintain an appropriate response against all antigens. In vitro analysis indicates that CD4⁺ CD25⁺ T cells act in a cell-contact-dependent manner resulting in the inhibition of IL-2 production in responding T cells. Recent reports show the localization of CD4⁺ CD25⁺ T cells in the draining lymph node and tissues involved in the immune response. These cells are seen in contact with both responding T cells and antigen-presenting cells (APC). Although, much in vivo data indicate that production of IL-10 is required for suppressive function, this work demonstrates that cell contact may also be a mechanism for CD4⁺ CD25⁺ T-cell-mediated suppression in vivo.

It was recently demonstrated that antibody signalling through the glucocorticoid-induced tumor necrosis factor receptor (TNFR) (GITR) regulates suppressor cell function. The ligand for GITR (GITR-L) has also been shown to overcome suppression by CD4⁺ CD25⁺ T cells. GITR-L is expressed on a broad range of APC. Perhaps

regulated expression of GITR-L controls the ability of responding cells to mount an appropriate immune response. Therapeutically targeting GITR/GITR-L interactions may allow for manipulation of CD4⁺ CD25⁺ T-cell-mediated suppression. Engagement of GITR would decrease suppressive function for induction of tumor immunity or enhancing vaccines. Conversely, blocking GITR-L could enhance their suppression for amelioration of autoimmunity or graft rejection.

Although much cellular and molecular characterization has been performed on these cells, there are still many unanswered questions. At the forefront are the following: How do CD4⁺ CD25⁺ T cells deliver the suppressive signal? What is the interaction of CD4⁺ CD25⁺ T cells with other regulatory T-cell populations or regulatory dendritic cells? Perhaps most important, will these “suppressor” cells stand the test of time?

ADDITIONAL READING

- BELKAID Y, PICCIRILLO CA, MENDEZ S, *et al*: CD4⁺ CD25⁺ immunoregulatory T lymphocytes control *Leishmania major* persistence and the development of concomitant immunity. *Nature* 420:502–507, 2002
- BLUESTONE JA, ABBAS AK: Natural versus adaptive regulatory T cells. *Nat Rev Immunol* 3:253–257, 2003
- HORI S, CARVALHO TL, DEMENGEOT J: CD25⁺ CD4⁺ regulatory T cells suppress CD4⁺ T cell-mediated pulmonary hyperinflammation driven by *Pneumocystis carinii* in immunodeficient mice. *Eur J Immunol* 32:1282–1291, 2002
- MCHUGH RS, SHEVACH EM: The role of suppressor T cells in regulation of immune responses. *J Allergy Clin Immunol* 110:693–702, 2002
- MCHUGH RS, WHITTERS MJ, PICCIRILLO CA, *et al*: CD4⁺ CD25⁺ immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. *Immunity* 16:311–323, 2002
- MOTTET C, UHLIG HH, POWRIE F: Cutting edge: Cure of colitis by CD4⁺ CD25⁺ regulatory T cells. *J Immunol* 170:3939–3943, 2003
- SHEVACH EM: CD4⁺ CD25⁺ suppressor T cells: More questions than answers. *Nat Rev Immunol* 2:389–400, 2002